Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 135-710, Korea.
Int J Hematol. 2013 Mar;97(3):403-8. doi: 10.1007/s12185-013-1286-z. Epub 2013 Feb 12.
Chronic lymphocytic leukemia (CLL) is a mature B-cell neoplasm characterized by the expansion of CD5-positive lymphocytes in peripheral blood. While CLL is the most common type of leukemia in Western populations, the disease is rare in Asians. Hence, clinical and laboratory data and studies of CLL in Asian populations have been limited. In this study, we investigated the clinical and laboratory characteristics of CLL in Korea. A total of 39 patients who had been diagnosed with CLL during the period from January 2000 to October 2010 at a single institution in Korea were examined. Clinically, 67 % of the patients were classified as having advanced Binet stages B or C. Up to 56 % of the patients had an atypical immunophenotype with high frequencies of FMC7 positivity and strong CD22 positivity. Twenty-six patients (67 %) received chemotherapy, and more than half of the treated patients (54 %) expired. The overall survival rate at 5 years was estimated at 71 %, which was lower than previously reported. These findings suggested that CLL in Korea has atypical immunophenotypes and that its clinical behavior may be more aggressive than that in Western populations.
慢性淋巴细胞白血病（CLL）是一种成熟 B 细胞肿瘤，其特征是外周血中 CD5 阳性淋巴细胞的扩增。虽然 CLL 是西方人群中最常见的白血病类型，但在亚洲人群中该疾病较为罕见。因此，亚洲人群中 CLL 的临床和实验室数据及研究有限。在这项研究中，我们研究了韩国的 CLL 临床和实验室特征。共检查了 39 例于 2000 年 1 月至 2010 年 10 月在韩国的一家单一机构被诊断为 CLL 的患者。临床上，67%的患者被归类为具有晚期 Binet 分期 B 或 C。高达 56%的患者具有非典型免疫表型，FMC7 阳性和 CD22 阳性较强的频率较高。26 例患者（67%）接受了化疗，超过一半的治疗患者（54%）死亡。5 年总生存率估计为 71%，低于之前的报道。这些发现表明韩国的 CLL 具有非典型免疫表型，其临床行为可能比西方人群更为激进。
